Inventor
PETERS ROBERT T
US48 patents
⚠️ This page may combine multiple inventors who share the name “PETERS ROBERT T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOVERATIV THERAPEUTICS INC
31 patentsUS9867873B2Jan 16, 2018
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC17 citations94
US10138291B2Nov 27, 2018
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
BIOVERATIV THERAPEUTICS INC30 citations92
US9675676B2Jun 13, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC19 citations92
US9629903B2Apr 25, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC17 citations92
US9623091B2Apr 18, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC16 citations92
US9636416B2May 2, 2017
Immunoglobulin chimeric monomer-dimer hybrids
BIOVERATIV THERAPEUTICS INC20 citations91
US11192936B2Dec 7, 2021
Factor VIII chimeric proteins and uses thereof
BIOVERATIV THERAPEUTICS INC10 citations84
US10898554B1Jan 26, 2021
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC6 citations84
US10568943B2Feb 25, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC6 citations84
US10561714B2Feb 18, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC3 citations84
US10548954B2Feb 4, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC5 citations84
US10370431B2Aug 6, 2019
Optimized factor VIII gene
BIOVERATIV THERAPEUTICS INC6 citations84
US9725496B1Aug 8, 2017
Immunoglobulin chimeric monomer-dimer hybrids
BIOVERATIV THERAPEUTICS INC4 citations84
US10881742B2Jan 5, 2021
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
BIOVERATIV THERAPEUTICS INC5 citations83
US10548953B2Feb 4, 2020
Factor VIII-XTEN fusions and uses thereof
BIOVERATIV THERAPEUTICS INC6 citations83
US11091534B2Aug 17, 2021
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
BIOVERATIV THERAPEUTICS INC8 citations82
US10287564B2May 14, 2019
Procoagulant compounds
BIOVERATIV THERAPEUTICS INC5 citations81
US12186375B2Jan 7, 2025
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
BIOVERATIV THERAPEUTICS INC1 citations73
US11168125B2Nov 9, 2021
Immunoglobulin chimeric monomer-dimer hybrids
BIOVERATIV THERAPEUTICS INC1 citations73
US11008561B2May 18, 2021
Optimized factor IX gene
BIOVERATIV THERAPEUTICS INC4 citations73
US11370827B2Jun 28, 2022
Chimeric factor VIII polypeptides and uses thereof
BIOVERATIV THERAPEUTICS INC5 citations72
US11225650B2Jan 18, 2022
Methods of using FIX polypeptides
BIOVERATIV THERAPEUTICS INC5 citations72
US10927362B2Feb 23, 2021
Processable single chain molecules and polypeptides made using same
BIOVERATIV THERAPEUTICS INC1 citations71
US10745680B2Aug 18, 2020
Factor IX fusion proteins and methods of making and using same
BIOVERATIV THERAPEUTICS INC6 citations69
US12275970B2Apr 15, 2025
Optimized factor IX gene
BIOVERATIV THERAPEUTICS INC1 citations64
US11787851B2Oct 17, 2023
Optimized factor VIII gene
BIOVERATIV THERAPEUTICS INC1 citations62
US11401322B2Aug 2, 2022
Immunoglobulin chimeric monomer-dimer hybrids
BIOVERATIV THERAPEUTICS INC0 citations62
US11168316B2Nov 9, 2021
Chimeric clotting factors
BIOVERATIV THERAPEUTICS INC0 citations57
US12168776B2Dec 17, 2024
Nucleic acid molecules and uses thereof
BIOVERATIV THERAPEUTICS INC1 citations53
US12364774B2Jul 22, 2025
Nucleic acid molecules and uses thereof for non-viral gene therapy
BIOVERATIV THERAPEUTICS INC0 citations52
US10202595B2Feb 12, 2019
Chimeric clotting factors
BIOVERATIV THERAPEUTICS INC0 citations43
SYNTONIX PHARMACEUTICALS INC
8 patentsUS7862820B2Jan 4, 2011
Immunoglobulin chimeric monomer-dimer hybrids
SYNTONIX PHARMACEUTICALS INC120 citations98
US7404956B2Jul 29, 2008
Immunoglobulin chimeric monomer-dimer hybrids
SYNTONIX PHARMACEUTICALS INC301 citations98
US7381408B2Jun 3, 2008
Methods for chemically synthesizing immunoglobulin chimeric proteins
SYNTONIX PHARMACEUTICALS INC173 citations98
US7348004B2Mar 25, 2008
Immunoglobulin chimeric monomer-dimer hybrids
SYNTONIX PHARMACEUTICALS INC218 citations98
US7820162B2Oct 26, 2010
Methods for chemically synthesizing immunoglobulin chimeric proteins
SYNTONIX PHARMACEUTICALS INC26 citations96
US7566565B2Jul 28, 2009
PC5 as a factor IX propeptide processing enzyme
SYNTONIX PHARMACEUTICALS INC44 citations96
US8021880B2Sep 20, 2011
PC5 as a factor IX propeptide processing enzyme
SYNTONIX PHARMACEUTICALS INC17 citations92
US7795400B2Sep 14, 2010
PC5 as a factor IX propeptide processing enzyme
SYNTONIX PHARMACEUTICALS INC10 citations84